Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30833332 | 0.87 | MAPT (0.40) | ALDH1A1HSD17B2HSD17B1KMT2AMEN1 | |
| SCHEMBL9956630 | 0.82 | HSD17B2 (0.60) | HSD17B2HSD17B1 | |
| SCHEMBL18612985 | 0.82 | ALDH1A1 (0.49) | ALDH1A1HSD17B2HSD17B1KMT2APOLB | |
| SCHEMBL29460229 | 0.82 | ALDH1A1 (0.46) | ALDH1A1HSD17B2HSD17B1KMT2APOLB | |
| SCHEMBL31034446 | 0.80 | ALDH1A1 (0.44) | ALDH1A1HSD17B2HSD17B1KMT2APOLB | |
| SCHEMBL11854125 | 0.80 | ALDH1A1 (0.51) | ALDH1A1KMT2APOLBHSP90AA1PDK1 | |
| SCHEMBL17460819 | 0.78 | HSP90AA1 (0.50) | ALDH1A1HSD17B2HSD17B1KMT2APOLB | |
| SCHEMBL28391490 | 0.74 | ALDH1A1 (0.38) | ALDH1A1HSD17B2HSD17B1KMT2ARXRA | |
| SCHEMBL18593560 | 0.72 | TSPO (0.48) | ALDH1A1HSD17B2HSD17B1KMT2APOLB | |
| SCHEMBL30743887 | 0.72 | MTNR1A (0.50) | HSD17B2HSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288537-B2 | Azetidine derivatives as CCR-3 receptor antagonists | NOVARTIS AG (CH) | 2007-10-30 | — | — | US | disclosed |
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| CN-1638761-A | Azetidine derivatives as CCR-3 receptor antagonists | NOVARTIS AG (CH) | 2005-07-13 | — | — | CN | disclosed |
| EP-1487435-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003077907-A1 | AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222118-A1 | Azetidine derivatives as ccr-3 receptor antagonists | CCR3, CCR1, CCR9 | ALDH1A1 2840/4885HSD17B2 3607/4885HSD17B1 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.